Keros Therapeutics vs Lineage Cell Therapeutics
Keros Therapeutics is the larger business, with $244m of revenue in fiscal 2025 against $14.6m for Lineage Cell Therapeutics (16.8 times as much). Keros Therapeutics grew faster (6769.4% against 53.2%). Keros Therapeutics kept more of each dollar of sales as profit: a net margin of 35.7% against -436.5%.
| Latest fiscal year | Keros TherapeuticsKROS, 2025 | Lineage Cell TherapeuticsLCTX, 2025 |
|---|---|---|
| Revenue | $244m | $14.6m |
| Revenue growth | 6769.4% | 53.2% |
| Net income | $87.0m | −$63.5m |
| Operating margin | 27.7% | — |
| Net margin | 35.7% | -436.5% |
| Return on equity | 19.9% | -103.4% |
| Free cash flow | $106m | −$19.4m |
| Cash | $287m | $40.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $375m | — |
| Employees | 78 | 77 |
| Market value | $215m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 21 (Weak) |
| Insider trades, 12 months | 6 buys, 12 sales | 1 buys, 0 sales |